J.W. Cole Advisors Inc. Trims Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

J.W. Cole Advisors Inc. lessened its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRXFree Report) by 37.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,600 shares of the biotechnology company’s stock after selling 7,500 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in BioCryst Pharmaceuticals were worth $64,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Quarry LP purchased a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter worth approximately $54,000. Tower Research Capital LLC TRC lifted its position in shares of BioCryst Pharmaceuticals by 131.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,420 shares of the biotechnology company’s stock worth $62,000 after buying an additional 5,912 shares during the last quarter. JGP Global Gestao de Recursos Ltda. purchased a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter worth approximately $64,000. MA Private Wealth acquired a new position in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $76,000. Finally, Counterweight Ventures LLC acquired a new position in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $81,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Anthony Doyle bought 36,300 shares of the firm’s stock in a transaction on Tuesday, May 14th. The shares were bought at an average cost of $5.57 per share, for a total transaction of $202,191.00. Following the transaction, the chief financial officer now owns 266,744 shares of the company’s stock, valued at $1,485,764.08. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CFO Anthony Doyle bought 36,300 shares of the firm’s stock in a transaction on Tuesday, May 14th. The shares were bought at an average cost of $5.57 per share, for a total transaction of $202,191.00. Following the transaction, the chief financial officer now owns 266,744 shares of the company’s stock, valued at $1,485,764.08. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Helen M. Thackray bought 30,000 shares of the firm’s stock in a transaction on Tuesday, May 14th. The shares were bought at an average price of $5.86 per share, for a total transaction of $175,800.00. Following the completion of the transaction, the insider now directly owns 272,139 shares in the company, valued at approximately $1,594,734.54. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 103,601 shares of company stock worth $596,338. Corporate insiders own 4.80% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX opened at $6.52 on Monday. The stock has a market capitalization of $1.35 billion, a P/E ratio of -6.09 and a beta of 1.88. The company’s fifty day moving average is $6.01 and its two-hundred day moving average is $5.64. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $7.95.

BioCryst Pharmaceuticals (NASDAQ:BCRXGet Free Report) last announced its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.06. The firm had revenue of $92.80 million during the quarter, compared to analyst estimates of $85.62 million. The business’s quarterly revenue was up 34.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.28) earnings per share. Sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.66 EPS for the current year.

Wall Street Analyst Weigh In

BCRX has been the topic of a number of recent research reports. JMP Securities lifted their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a report on Tuesday, May 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $12.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $14.00.

Check Out Our Latest Stock Report on BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Profile

(Free Report)

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

Featured Articles

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRXFree Report).

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.